Reduction Of Angiotensin Ii Induced Hypertension And Cardiac Fibrosis With Glp-1 Receptor Agonist And Dpp-4 Inhibitor Via Decreasing Nadph Oxidase Expression
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Banks, TrentonKeyword
School of Medicine
Metadata
Show full item recordTitle
Reduction Of Angiotensin Ii Induced Hypertension And Cardiac Fibrosis With Glp-1 Receptor Agonist And Dpp-4 Inhibitor Via Decreasing Nadph Oxidase ExpressionAbstract
Objectives: Preservation of plasma glucagon-like peptide-1 (GLP-1) has been demonstrated to be cardioprotective in animals and patients. This study aims to investigate the mechanisms of action underlying cardioprotection by enhancing GLP-1 level through inhibiting NADPH oxidase mediated signaling. Methods: The study was performed in the Sprague-Dawley rat model of angiotensin II (Ang II) infusion (500 ng/kg/min) using osmotic minipumps for 4 weeks. GLP-1 agonist liraglutide (0.3 mg/kg, injected subcutaneously twice daily) and dipeptidyl peptidease-4 inhibitor, linagliptin (8 mg/kg, administered via oral gavage) were selected to preserve GLP-1 level. Blood pressure was measured noninvasively. Aorta and heart were saved for histological analysis. Results: Relative to the animals with Ang II infusion, in the aorta, treatment with liraglutide and linagliptin significantly downregulated the expression of NOX4/ICAM-1, and enhanced eNOS expression. Aortic wall thickness was reduced comparatively (267.4 ±22.5µm and 286.6 ±25.5µm vs. 339.7 ±40.4µm in Ang II group, all p<0.05); with a significant reduction in mean blood pressure in these two groups (121±19 and 139±16 mmHg vs. 163±30 mmHg in Ang II group, all p<0.05). In the heart, liraglutide and linagliptin comparatively reduced the protein levels of NOX4 and TGFβ1 and expression of MCP-1, as well as attenuated the proliferation of myofibroblasts (15.1±4.9 and 13.3±3.6 vs. 42.8±22.6/HPF in Ang II group, all p<0.05). Furthermore, mitochondrial structure damaged by Ang II was significantly preserved by liraglutide and linagliptin, in company with a significant reduction in cardiac fibrosis. Conclusion: Taken together, these results suggest that the preservation of GLP-1 level with exogenous supply of GLP-1 with liraglutide or prevention of endogenous degradation of GLP-1 with linagliptin protects against Ang II induced injury in aorta and heart, primarily mediated by inhibiting NOX-mediated signaling.Collections